290 related articles for article (PubMed ID: 21647730)
1. Progressive multifocal leukoencephalopathy and natalizumab.
Hellwig K; Gold R
J Neurol; 2011 Nov; 258(11):1920-8. PubMed ID: 21647730
[TBL] [Abstract][Full Text] [Related]
2. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab in relapsing-remitting multiple sclerosis.
Outteryck O
Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.
McCormack PL
Drugs; 2013 Sep; 73(13):1463-81. PubMed ID: 23912625
[TBL] [Abstract][Full Text] [Related]
5. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
Walker A; Watson C; Alexopoulos ST; Deniz B; Arnold R; Bates D
Curr Med Res Opin; 2014 Apr; 30(4):629-35. PubMed ID: 24289170
[TBL] [Abstract][Full Text] [Related]
6. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
Kappos L; Bates D; Edan G; Eraksoy M; Garcia-Merino A; Grigoriadis N; Hartung HP; Havrdová E; Hillert J; Hohlfeld R; Kremenchutzky M; Lyon-Caen O; Miller A; Pozzilli C; Ravnborg M; Saida T; Sindic C; Vass K; Clifford DB; Hauser S; Major EO; O'Connor PW; Weiner HL; Clanet M; Gold R; Hirsch HH; Radü EW; Sørensen PS; King J
Lancet Neurol; 2011 Aug; 10(8):745-58. PubMed ID: 21777829
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab and progressive multifocal leucoencephalopathy.
Berger JR
Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii48-53. PubMed ID: 17038473
[TBL] [Abstract][Full Text] [Related]
9. [Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?].
Warnke C; Adams O; Gold R; Hartung HP; Hohlfeld R; Wiendl H; Kieseier BC
Nervenarzt; 2011 Apr; 82(4):475-80. PubMed ID: 21240604
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
Lanza Cariccio V; Bramanti P; Mazzon E
Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
12. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
Ziemssen T; Gass A; Wuerfel J; Bayas A; Tackenberg B; Limmroth V; Linker R; Mäurer M; Haas J; Stangel M; Meergans M; Harlin O; Hartung HP
BMC Neurol; 2016 Jul; 16():98. PubMed ID: 27405225
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
Yousry TA; Major EO; Ryschkewitsch C; Fahle G; Fischer S; Hou J; Curfman B; Miszkiel K; Mueller-Lenke N; Sanchez E; Barkhof F; Radue EW; Jäger HR; Clifford DB
N Engl J Med; 2006 Mar; 354(9):924-33. PubMed ID: 16510746
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.
Kappos L; Bates D; Hartung HP; Havrdova E; Miller D; Polman CH; Ravnborg M; Hauser SL; Rudick RA; Weiner HL; O'Connor PW; King J; Radue EW; Yousry T; Major EO; Clifford DB
Lancet Neurol; 2007 May; 6(5):431-41. PubMed ID: 17434098
[TBL] [Abstract][Full Text] [Related]
15. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
16. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.
Toorop AA; van Lierop ZYG; Strijbis EEM; Teunissen CE; Petzold A; Wattjes MP; Barkhof F; de Jong BA; van Kempen ZLE; Killestein J
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33051344
[TBL] [Abstract][Full Text] [Related]
17. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Rath L; Vijiaratnam N; Skibina O
Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
[TBL] [Abstract][Full Text] [Related]
18. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.
Langer-Gould A; Steinman L
Curr Neurol Neurosci Rep; 2006 May; 6(3):253-8. PubMed ID: 16635435
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.
Ghezzi A; Grimaldi LM; Marrosu MG; Pozzilli C; Comi G; Bertolotto A; Trojano M; Gallo P; Capra R; Centonze D; Millefiorini E; Sotgiu S; Brescia Morra V; Amato MP; Lugaresi A; Mancardi G; Caputo D; Montanari E; Provinciali L; Durelli L; Bergamaschi R; Bellantonio P; Tola MR; Cottone S; Savettieri G; Tedeschi G;
Neurol Sci; 2011 Apr; 32(2):351-8. PubMed ID: 21234775
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
